{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:59:35Z","timestamp":1791140375368,"version":"4.1.0"},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Perinatal sepsis constitutes a medical emergency and is still one of the major causes of mortality and morbidity. The possibility of an early diagnosis of sepsis is\u00a0still debated and controversial. In particular, clinical symptoms can be hidden by the association of sepsis with other perinatal diseases and\/or by therapeutic strategies performed. In this context, there is evidence that the accuracy of standard of care diagnostic parameters (i.e. blood culture, C-reactive protein, procalcitonin) can be biased by additional confounding factors (gestational age, birth-weight, acute-chronic hypoxia). Therefore, the inclusion in clinical daily practice of new biomarkers of sepsis is of utmost importance. Of a panel of biomarkers, Presepsin (P-SEP) plays an important role in the development and response of the immune system and as an early marker of sepsis both in adult and pediatric patients. Therefore, in the present review we aim to offer an overview of the role of P-SEP in the early detection of perinatal sepsis as a trustworthy marker according to actual statements of official international institutions. Future perspectives regard the possibility of a longitudinal non-invasive biological fluids P-SEP assessment thus limiting the sample stress in high risk newborns.<\/jats:p>","DOI":"10.1515\/cclm-2022-0277","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T13:53:12Z","timestamp":1652449992000},"page":"1136-1144","source":"Crossref","is-referenced-by-count":19,"title":["Perinatal presepsin assessment: a new sepsis diagnostic tool?"],"prefix":"10.1515","volume":"60","author":[{"given":"Valentina","family":"Botondi","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebe","family":"D\u2019Adamo","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-1711","authenticated-orcid":false,"given":"Mario","family":"Plebani","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , University Hospital of Padova , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Trubiani","sequence":"additional","affiliation":[{"name":"Department of Innovative Technologies in Medicine & Dentistry , University \u201cG. D\u2019Annunzio\u201d , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Ricco","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynzia","family":"Spagnuolo","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Barbante","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Strozzi","sequence":"additional","affiliation":[{"name":"AO SS Antonio, Biagio and C. Arrigo Hospital , Alessandria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maconi","sequence":"additional","affiliation":[{"name":"AO SS Antonio, Biagio and C. Arrigo Hospital , Alessandria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gazzolo","sequence":"additional","affiliation":[{"name":"Magna Graecia University , Catanzaro , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Betti","sequence":"additional","affiliation":[{"name":"AO SS Antonio, Biagio and C. Arrigo Hospital , Alessandria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1904-7277","authenticated-orcid":false,"given":"Annalisa","family":"Roveta","sequence":"additional","affiliation":[{"name":"AO SS Antonio, Biagio and C. Arrigo Hospital , Alessandria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Levantini","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Gazzolo","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit , G. D\u2019Annunzio University , Chieti , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2023033111252085233_j_cclm-2022-0277_ref_001","unstructured":"Chen, L, Xiao, T, Luo, Y, Qiu, Q, Que, R, Huang, X, et al.. Soluble CD14 subtype (sCD14-ST) is a biomarker for neonatal sepsis. Int J Clin Exp Pathol 2017;10:9718\u201324."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_002","doi-asserted-by":"crossref","unstructured":"Gad, GI, Shinkar, DM, Kamel El-Din, MM, Nagi, HM. The utility of soluble CD14 subtype in early diagnosis of culture-proven early-onset neonatal sepsis and prediction of outcome. Am J Perinatol 2020;37:497\u2013502. https:\/\/doi.org\/10.1055\/s-0039-1683863.","DOI":"10.1055\/s-0039-1683863"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_003","unstructured":"Singh, M, Alsaleem, M, Gray, CP. Neonatal sepsis. Treasure Island (FL): StatPearls; 2021."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_004","doi-asserted-by":"crossref","unstructured":"Ahmed, AM, Mohammed, AT, Bastawy, S, Attalla, HA, Yousef, A, Abdelrazek, MS, et al.. Serum biomarkers for the early detection of the early-onset neonatal sepsis: a single-center prospective study. Adv Neonatal Care 2019;19:E26\u201332. https:\/\/doi.org\/10.1097\/anc.0000000000000631.","DOI":"10.1097\/ANC.0000000000000631"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_005","doi-asserted-by":"crossref","unstructured":"Shah, BA, Padbury, JF. Neonatal sepsis: an old problem with new insights. Virulence 2014;5:170\u20138. https:\/\/doi.org\/10.4161\/viru.26906.","DOI":"10.4161\/viru.26906"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_006","doi-asserted-by":"crossref","unstructured":"Keij, FM, Kornelisse, RF, Tramper-Stranders, GA, Allegaert, K, Allegaert, K. Improved pathogen detection in neonatal sepsis to boost antibiotic stewardship. Future Microbiol 2020;15:461\u20134. https:\/\/doi.org\/10.2217\/fmb-2019-0334.","DOI":"10.2217\/fmb-2019-0334"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_007","doi-asserted-by":"crossref","unstructured":"van Maldeghem, I, Nusman, CM, Visser, DH. Soluble CD14 subtype (sCD14-ST) as biomarker in neonatal early-onset sepsis and late-onset sepsis: a systematic review and meta-analysis. BMC Immunol 2019;20:17. https:\/\/doi.org\/10.1186\/s12865-019-0298-8.","DOI":"10.1186\/s12865-019-0298-8"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_008","doi-asserted-by":"crossref","unstructured":"Mussap, M, Puxeddu, E, Puddu, M, Ottonello, G, Coghe, F, Comite, P, et al.. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS. Clin Chim Acta 2015;451:65\u201370. https:\/\/doi.org\/10.1016\/j.cca.2015.07.025.","DOI":"10.1016\/j.cca.2015.07.025"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_009","unstructured":"Kamel, M, Abd-ullah, H, El Sayed, M, Abdel Aziz, R. Presepsin as an early predictor of neonatal sepsis. Int J Pediatr 2021;9:13359\u201369."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_010","doi-asserted-by":"crossref","unstructured":"Dr\u0103goescu, AN, P\u0103dureanu, V, St\u0103nculescu, AD, Chiu\u021bu, LC, Florescu, DN, Gheonea, IA, et al.. Presepsin as a potential prognostic marker for sepsis according to actual practice guidelines. J Personalized Med 2020;11:2. https:\/\/doi.org\/10.3390\/jpm11010002.","DOI":"10.3390\/jpm11010002"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_011","doi-asserted-by":"crossref","unstructured":"Sakyi, SA, Enimil, A, Adu, DK, Ephraim, RD, Danquah, KO, Fondjo, L, et al.. Individual and combined bioscore model of presepsin, procalcitonin, and high sensitive C-reactive protein as biomarkers for early diagnosis of paediatric sepsis. Heliyon 2020;6:e04841. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04841.","DOI":"10.1016\/j.heliyon.2020.e04841"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_012","doi-asserted-by":"crossref","unstructured":"Turhan, EE, G\u00fcrsoy, T, Oval\u0131, F. Factors which affect mortality in neonatal sepsis. Turk Pediatri Ars 2015;50:170\u20135. https:\/\/doi.org\/10.5152\/turkpediatriars.2015.2627.","DOI":"10.5152\/TurkPediatriArs.2015.2627"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_013","doi-asserted-by":"crossref","unstructured":"Fleischmann, C, Reichert, F, Cassini, A, Horner, R, Harder, T, Markwart, R, et al.. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child 2021;106:745\u201352. https:\/\/doi.org\/10.1136\/archdischild-2020-320217.","DOI":"10.1136\/archdischild-2020-320217"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_014","doi-asserted-by":"crossref","unstructured":"Shane, AL, S\u00e1nchez, PJ, Stoll, BJ. Neonatal sepsis. Lancet 2017;390:1770\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(17)31002-4.","DOI":"10.1016\/S0140-6736(17)31002-4"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_015","doi-asserted-by":"crossref","unstructured":"Pugni, L, Pietrasanta, C, Milani, S, Vener, C, Ronchi, A, Falbo, M, et al.. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One 2015;10:e0146020. https:\/\/doi.org\/10.1371\/journal.pone.0146020.","DOI":"10.1371\/journal.pone.0146020"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_016","doi-asserted-by":"crossref","unstructured":"Sinha, M, Jupe, J, Mack, H, Coleman, TP, Lawrence, SM, Fraley, SI. Emerging technologies for molecular diagnosis of sepsis. Clin Microbiol Rev 2018;31:e00089\u201317. https:\/\/doi.org\/10.1128\/CMR.00089-17.","DOI":"10.1128\/CMR.00089-17"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_017","doi-asserted-by":"crossref","unstructured":"Maddaloni, C, De Rose, DU, Santisi, A, Martini, L, Caoci, S, Bersani, I, et al.. The emerging role of presepsin (P-SEP) in the diagnosis of sepsis in the critically ill infant: a literature review. Int J Mol Sci 2021;22:12154. https:\/\/doi.org\/10.3390\/ijms222212154.","DOI":"10.3390\/ijms222212154"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_018","unstructured":"U.S Food and Drug Administration Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Biomarker qualification: evidentiary framework guidance for industry and FDA staff. Rockville, MD: Department of Health and Human Services; 2018."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_019","unstructured":"European Medicines Agency. Essential considerations for successful qualification of novel methodologies EMA\/750178\/2017. Geneva, Switzerland: European Medicines Agency; 2017."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_020","doi-asserted-by":"crossref","unstructured":"Hunter, DJ, Losina, E, Guermazi, A, Burstein, D, Lassere, MN, Kraus, V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets 2010;11:536\u201345. https:\/\/doi.org\/10.2174\/138945010791011947.","DOI":"10.2174\/138945010791011947"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_021","doi-asserted-by":"crossref","unstructured":"Wright, SD, Ramos, RA, Tobias, PS, Ulevitch, RJ, Mathison, JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431\u20133. https:\/\/doi.org\/10.1126\/science.1698311.","DOI":"10.1126\/science.1698311"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_022","doi-asserted-by":"crossref","unstructured":"Arroyo-Espliguero, R, Avanzas, P, Jeffery, S, Kaski, JC. CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart 2004;90:983\u20138. https:\/\/doi.org\/10.1136\/hrt.2002.001297.","DOI":"10.1136\/hrt.2002.001297"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_023","unstructured":"Alhajj, M, Farhana, A. Enzyme linked immunosorbent assay. Treasure Island (FL): StatPearls; 2021."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_024","unstructured":"Tate, J, Ward, G. Interferences in immunoassay. Clin Biochem Rev 2004;25:105\u201320."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_025","doi-asserted-by":"crossref","unstructured":"Okamura, Y, Yokoi, H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011;412:2157\u201361. https:\/\/doi.org\/10.1016\/j.cca.2011.07.024.","DOI":"10.1016\/j.cca.2011.07.024"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_026","doi-asserted-by":"crossref","unstructured":"Mussap, M, Puxeddu, E, Burrai, P, Noto, A, Cibecchini, F, Testa, M, et al.. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012;25:51\u20133. https:\/\/doi.org\/10.3109\/14767058.2012.717462.","DOI":"10.3109\/14767058.2012.717462"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_027","doi-asserted-by":"crossref","unstructured":"Poggi, C, Vasarri, MV, Boni, L, Pugni, L, Mosca, F, Dani, C. Reference ranges of Presepsin in preterm infants in the first 48\u00a0h of life: a multicenter observational study. Clin Chim Acta 2020;508:191\u20136. https:\/\/doi.org\/10.1016\/j.cca.2020.05.040.","DOI":"10.1016\/j.cca.2020.05.040"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_028","doi-asserted-by":"crossref","unstructured":"Nur Ergor, S, Yalaz, M, Altun Koroglu, O, Sozmen, E, Akisu, M, Kultursay, N. Reference ranges of presepsin (soluble CD14 subtype) in term and preterm neonates without infection, in relation to gestational and postnatal age, in the first 28\u00a0days of life. Clin Biochem 2020;77:7\u201313. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.12.007.","DOI":"10.1016\/j.clinbiochem.2019.12.007"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_029","doi-asserted-by":"crossref","unstructured":"K\u00f6stlin-Gille, N, H\u00e4rtel, C, Haug, C, Gopel, W, Zemlin, M, Muller, A, et al.. Epidemiology of early and late onset neonatal sepsis in very low birthweight infants: data from the German neonatal network. Pediatr Infect Dis J 2021;40:255\u20139.","DOI":"10.1097\/INF.0000000000002976"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_030","doi-asserted-by":"crossref","unstructured":"De\u011firmencio\u011flu, H, Ozer Bekmez, B, Derme, T, \u00d6ncel, MY, Canpolat, FE, Tayman, C. Presepsin and fetuin-a dyad for the diagnosis of proven sepsis in preterm neonates. BMC Infect Dis 2019;19:695.","DOI":"10.1186\/s12879-019-4316-5"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_031","doi-asserted-by":"crossref","unstructured":"Miyosawa, Y, Akazawa, Y, Kamiya, M, Nakamura, C, Takeuchi, Y, Kusakari, M, et al.. Presepsin as a predictor of positive blood culture in suspected neonatal sepsis. Pediatr Int 2018;60:157\u201361. https:\/\/doi.org\/10.1111\/ped.13469.","DOI":"10.1111\/ped.13469"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_032","doi-asserted-by":"crossref","unstructured":"Montaldo, P, Rosso, R, Santantonio, A, Chello, G, Giliberti, P. Presepsin for the detection of early-onset sepsis in preterm newborns. Pediatr Res 2017;81:329\u201334. https:\/\/doi.org\/10.1038\/pr.2016.217.","DOI":"10.1038\/pr.2016.217"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_033","doi-asserted-by":"crossref","unstructured":"Topcuoglu, S, Arslanbuga, C, Gursoy, T, Aktas, A, Karatekin, G, Uluhan, R, et al.. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Fetal Neonatal Med 2016;29:1834\u20139. https:\/\/doi.org\/10.3109\/14767058.2015.1064885.","DOI":"10.3109\/14767058.2015.1064885"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_034","doi-asserted-by":"crossref","unstructured":"Hashem, HE, Abdel Halim, RM, El Masry, SA, Mokhtar, AM, Abdelaal, NM. The utility of neutrophil CD64 and presepsin as diagnostic, prognostic, and monitoring biomarkers in neonatal sepsis. Internet J Microbiol 2020;2020:8814892. https:\/\/doi.org\/10.1155\/2020\/8814892.","DOI":"10.1155\/2020\/8814892"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_035","doi-asserted-by":"crossref","unstructured":"Ozdemir, AA, Elgormus, Y. Diagnostic value of presepsin in detection of early-onset neonatal sepsis. Am J Perinatol 2017;34:550\u20136. https:\/\/doi.org\/10.1055\/s-0036-1593851.","DOI":"10.1055\/s-0036-1593851"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_036","doi-asserted-by":"crossref","unstructured":"Sabry, JH, Elfeky, OA, Elsadek, AE, Eldaly, AE. Presepsin as an early reliable diagnostic and prognostic marker of neonatal sepsis. Int J Adv Res 2016;6:1538\u201349. https:\/\/doi.org\/10.21474\/ijar01\/716.","DOI":"10.21474\/IJAR01\/716"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_037","doi-asserted-by":"crossref","unstructured":"Pietrasanta, C, Ronchi, A, Vener, C, Poggi, C, Ballerini, C, Testa, L, et al.. Presepsin (soluble CD14 subtype) as an early marker of neonatal sepsis and septic shock: a prospective diagnostic trial. Antibiotics 2021;10:580. https:\/\/doi.org\/10.3390\/antibiotics10050580.","DOI":"10.3390\/antibiotics10050580"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_038","doi-asserted-by":"crossref","unstructured":"Marazzi, MG, Randelli, F, Brioschi, M, Drago, L, Roman\u00f2, CL, Banfi, G, et al.. Presepsin: a potential biomarker of PJI? A comparative analysis with known and new infection biomarkers. Int J Immunopathol Pharmacol 2018;31:394632017749356.","DOI":"10.1177\/0394632017749356"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_039","doi-asserted-by":"crossref","unstructured":"Cortese, F, Scicchitano, P, Gesualdo, M, Filannino, A, De Giorgi, E, Schettini, F, et al.. Early and late infections in newborns: where do we stand? A review. Pediatr Neonatol 2016;57:265\u201373. https:\/\/doi.org\/10.1016\/j.pedneo.2015.09.007.","DOI":"10.1016\/j.pedneo.2015.09.007"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_040","doi-asserted-by":"crossref","unstructured":"Poggi, C, Bianconi, T, Gozzini, E, Generoso, M, Dani, C. Presepsin for the detection of late-onset sepsis in preterm newborns. Pediatrics 2015;135:68\u201375. https:\/\/doi.org\/10.1542\/peds.2014-1755.","DOI":"10.1542\/peds.2014-1755"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_041","doi-asserted-by":"crossref","unstructured":"Abd Almonaem, ER, Rashad, MM, Emam, HM, El-Shimi, OS. Tracheal aspirate presepsin: a promising biomarker in early onset neonatal pneumonia. Scand J Clin Lab Invest 2021;81:406\u201312. https:\/\/doi.org\/10.1080\/00365513.2021.1931709.","DOI":"10.1080\/00365513.2021.1931709"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_042","doi-asserted-by":"crossref","unstructured":"Koh, JH, Lee, S, Kim, HS, Lee, K, Lee, CS, Yoo, SA, et al.. Development of monitoring system for assessing rheumatoid arthritis within 5\u00a0minutes using a drop of bio-fluids. J Clin Med 2020;9:3499. https:\/\/doi.org\/10.3390\/jcm9113499.","DOI":"10.3390\/jcm9113499"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_043","doi-asserted-by":"crossref","unstructured":"Kang, MJ, Park, YJ, You, S, Yoo, SA, Choi, S, Kim, DH, et al.. Urinary proteome profile predictive of disease activity in rheumatoid arthritis. J Proteome Res 2014;13:5206\u201317. https:\/\/doi.org\/10.1021\/pr500467d.","DOI":"10.1021\/pr500467d"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_044","doi-asserted-by":"crossref","unstructured":"Bussolati, B, David, S, Cambi, V, Tobias, PS, Camussi, G. Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med 2002;10:441\u20139. https:\/\/doi.org\/10.3892\/ijmm.10.4.441.","DOI":"10.3892\/ijmm.10.4.441"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_045","unstructured":"Biria, M, Sattari, M, Vahid Golpayegani, M, Kooshki, F. Association of salivary sCD14 concentration levels with early childhood caries. Iran J Immunol 2010;7:193\u20137."},{"key":"2023033111252085233_j_cclm-2022-0277_ref_046","doi-asserted-by":"crossref","unstructured":"Staller, S, Lindsay, AK, Ramos, ED, Thomas, P, Srinivasan, M. Changes in salivary microbial sensing proteins CD14 and TLR2 with aging. Clin Oral Invest 2020;24:2523\u20138. https:\/\/doi.org\/10.1007\/s00784-020-03274-9.","DOI":"10.1007\/s00784-020-03274-9"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_047","doi-asserted-by":"crossref","unstructured":"Straus, RG. Neonatal anemia: pathophysiology and treatment. Immunol Invest 1995;24:341\u201351. https:\/\/doi.org\/10.3109\/08820139509062784.","DOI":"10.3109\/08820139509062784"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_048","doi-asserted-by":"crossref","unstructured":"Botondi, V, Pirra, A, Strozzi, M, Perrotta, M, Gavilanes, DAW, Di Ricco, L, et al.. Perinatal asphyxia partly affects presepsin urine levels in non-infected term infants. Clin Chem Lab Med 2022;60:793\u20139. https:\/\/doi.org\/10.1515\/cclm-2022-0027.","DOI":"10.1515\/cclm-2022-0027"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_049","doi-asserted-by":"crossref","unstructured":"Tsuchida, T, Ie, K, Okuse, C, Hirose, M, Nishisako, H, Torikai, K, et al.. Determining the factors affecting serum presepsin level and its diagnostic utility: a cross-sectional study. J Infect Chemother 2021;27:585\u201391. https:\/\/doi.org\/10.1016\/j.jiac.2020.11.013.","DOI":"10.1016\/j.jiac.2020.11.013"},{"key":"2023033111252085233_j_cclm-2022-0277_ref_050","doi-asserted-by":"crossref","unstructured":"Koizumi, Y, Sakanashi, D, Mohri, T, Watanabe, H, Shiota, A, Asai, N, et al.. Can presepsin uniformly respond to various pathogens? - an in\u00a0vitro assay of new sepsis marker. BMC Immunol 2020;21:33. https:\/\/doi.org\/10.1186\/s12865-020-00362-z.","DOI":"10.1186\/s12865-020-00362-z"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0277\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T14:58:39Z","timestamp":1680274719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0277\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,7,26]]}},"alternative-id":["10.1515\/cclm-2022-0277"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-0277","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}